Suchergebnisse - "Liu, Shihui"

PubPharm (203)

1

Functional Integrity of Radical SAM Enzyme Dph1•Dph2 Requires Non-Canonical Cofactor Motifs with Tandem Cysteines

enthalten in: Biomolecules | 2024

von Ütkür, K. | Mayer, K. | Liu, S. | +2

2

Targeting TAOK1 with resveratrol inhibits esophageal squamous cell carcinoma growth in vitro and in vivo

enthalten in: Molecular carcinogenesis | 2024

von Song, M. | Qu, Y. | Jia, H. | +10

3

Identification of ASF1A and HJURP by global H3-H4 histone chaperone analysis as a prognostic two-gene model in hepatocellular carcinoma

enthalten in: Scientific reports | 2024

von Liu, Y. | Liu, S. | Jing, R. | +8

4

Isolation, Identification, and Biological Characterization of Phage vB_KpnM_KpVB3 Targeting Carbapenem-Resistant Klebsiella pneumoniae ST11

enthalten in: Journal of global antimicrobial resistance | 2024

von Liu, S. | Xu, H. | Cao, R. | +2

5

LINC00540 promotes sorafenib resistance and functions as a ceRNA for miR-4677-3p to regulate AKR1C2 in hepatocellular carcinoma

enthalten in: Heliyon | 2024

von Xu, K. | Wang, X. | Hu, S. | +5

6

NADP+-dependent isocitrate dehydrogenase as a novel target for altering carbon flux to lipid accumulation and enhancing antioxidant capacity in Tetradesmus obliquus

enthalten in: Bioresource technology | 2024

von Li, J. | Wang, W. | Li, B. | +8

7

Single-cell transcriptomics reveals ferrimagnetic vortex iron oxide nanoring-mediated mild magnetic hyperthermia exerts antitumor effects by alleviating macrophage suppression in breast cancer

enthalten in: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2024

von Xi, P. | Liu, S. | Tang, J. | +9

8

PI3Kalpha/HDAC6 subtype selective dual inhibitor and application thereof

enthalten in: Europäisches Patentamt | 2023

von LYU XIAOQING | ZHANG YANFEI | GAO JINLAI | +1

9

PI3Kalpha/HDAC6 subtype selective dual inhibitor and application thereof

enthalten in: Europäisches Patentamt | 2023

von LYU XIAOQING | ZHANG YANFEI | GAO JINLAI | +1

10

Discovery of (S)-N1-(thiazol-2-yl) pyrrolidine-1,2-dicarboxamide derivatives targeting PI3Ka/HDAC6 for the treatment of cancer

enthalten in: Bioorganic & medicinal chemistry letters | 2023

von Zhang, Y. | Gao, J. | Wu, J. | +3

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[21]